Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 7 (July)

1. Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors.
   J Clin Oncol, 25(19): 2709-18. [Abstract] [Full-text]
2. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.
   J Clin Oncol, 25(19): 2656-63. [Abstract] [Full-text]
3. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
   J Clin Oncol, 25(19): 2650-5. [Abstract] [Full-text]
4. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
   J Clin Oncol, 25(19): 2664-70. [Abstract] [Full-text]
5. Stratification of breast cancer risk in women with atypia: a Mayo cohort study.
   J Clin Oncol, 25(19): 2671-7. [Abstract] [Full-text]
6. High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
   BMC Med Genet, 8: 32. [Abstract] [Full-text]
7. Plasma testosterone and prognosis of postmenopausal breast cancer patients.
   J Clin Oncol, 25(19): 2685-90. [Abstract] [Full-text]
8. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
   J Clin Oncol, 25(19): 2678-84. [Abstract] [Full-text]
9. Metabolomics: available results, current research projects in breast cancer, and future applications.
   J Clin Oncol, 25(19): 2840-6. [Abstract] [Full-text]
10. The role of genetic testing for cancer susceptibility in gynecologic practice.
    Obstet Gynecol, 110(1): 155-67. [Abstract] [Full-text]
11. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene.
    Cell, 129(7): 1275-86. [Abstract] [Full-text]
12. Salad vegetables dietary pattern protects against HER-2-positive breast cancer: a prospective Italian study.
    Int J Cancer, 121(4): 911-4. [Abstract] [Full-text]
13. Mutations and polymorphisms of the p21B transcript in breast cancer.
    Int J Cancer, 121(4): 908-10. [Abstract] [Full-text]
14. Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum.
    Int J Cancer, 121(4): 884-94. [Abstract] [Full-text]
15. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells.
    Int J Cancer, 121(4): 751-8. [Abstract] [Full-text]
16. Diabetes mellitus and risk of breast cancer: a meta-analysis.
    Int J Cancer, 121(4): 856-62. [Abstract] [Full-text]
17. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
    J Cell Physiol, 212(3): 690-701. [Abstract] [Full-text]
18. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis.
    Int J Cancer, 121(5): 1079-85. [Abstract] [Full-text]
19. Folate receptor overexpression is associated with poor outcome in breast cancer.
    Int J Cancer, 121(5): 938-42. [Abstract] [Full-text]
20. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity.
    Int J Cancer, 121(5): 1009-16. [Abstract] [Full-text]
21. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
    Int J Cancer, 121(5): 1017-20. [Abstract] [Full-text]
22. IGF-I plus E2 induces proliferation via activation of ROS-dependent ERKs and JNKs in human breast carcinoma cells.
    J Cell Physiol, 212(3): 666-74. [Abstract] [Full-text]
23. A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients.
    Int J Cancer, 121(5): 1036-46. [Abstract] [Full-text]
24. Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity.
    Int J Cancer, 121(5): 955-65. [Abstract] [Full-text]
25. AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology.
    J Cell Physiol, 212(3): 655-65. [Abstract] [Full-text]
26. Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment.
    Health Psychol, 26(4): 464-72. [Abstract] [Full-text]
27. Employment-contingent health insurance, illness, and labor supply of women: evidence from married women with breast cancer.
    Health Econ, 16(7): 719-37. [Abstract] [Full-text]
28. Genetic susceptibility for breast cancer: how many more genes to be found?
    Crit Rev Oncol Hematol, 63(2): 125-49. [Abstract] [Full-text]
29. Rising incidence rates of breast carcinoma with micrometastatic lymph node involvement.
    J Natl Cancer Inst, 99(13): 1044-9. [Abstract] [Full-text]
30. Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk.
    J Surg Oncol, 96(1): 46-53. [Abstract] [Full-text]
31. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    J Clin Oncol, 25(20): 2921-7. [Abstract] [Full-text]
32. Papillary lesions of the breast discovered on percutaneous large core and vacuum-assisted biopsies: reliability of clinical and pathological parameters in identifying benign lesions.
    Am J Surg, 194(2): 183-8. [Abstract] [Full-text]
33. Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients.
    Am J Surg, 194(2): 172-5. [Abstract] [Full-text]
34. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer.
    Cancer Res, 67(13): 6477-83. [Abstract] [Full-text]
35. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
    Cancer Res, 67(13): 6183-91. [Abstract] [Full-text]
36. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling.
    Cancer Res, 67(13): 6174-82. [Abstract] [Full-text]
37. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer.
    Cancer Res, 67(13): 6136-45. [Abstract] [Full-text]
38. Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.
    Cancer Res, 67(13): 6100-5. [Abstract] [Full-text]
39. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.
    Cancer Res, 67(13): 6064-74. [Abstract] [Full-text]
40. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    N Engl J Med, 357(2): 115-23. [Abstract] [Full-text]
41. Introduction of a breast cancer care programme including ultra short hospital stay in 4 early adopter centres: framework for an implementation study.
    BMC Cancer, 7: 117. [Abstract] [Full-text]
42. An extended age period cohort model for analysing (age, period)-tabulated data.
    Stat Med, 26(18): 3459-75. [Abstract] [Full-text]
43. A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer.
    Am J Epidemiol, 166(3): 246-54. [Abstract] [Full-text]
44. Apoptotic effect of Semecarpus anacardium nut extract on T47D breast cancer cell line.
    Cell Biol Int, 31(10): 1198-206. [Abstract] [Full-text]
45. Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers.
    Plast Reconstr Surg, 120(2): 390-8. [Abstract] [Full-text]
46. Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.
    Mutat Res, 632(1): 20-8. [Abstract] [Full-text]
47. Study of selected trace elements in cancerous and non-cancerous human breast tissues from Sudanese subjects using instrumental neutron activation analysis.
    Sci Total Environ, 383(1): 52-8. [Abstract] [Full-text]
48. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial.
    JAMA, 298(3): 289-98. [Abstract] [Full-text]
49. Accelerated intensity-modulated radiotherapy to breast in prone position: dosimetric results.
    Int J Radiat Oncol Biol Phys, 68(4): 1251-9. [Abstract] [Full-text]
50. Optimized dose coverage of regional lymph nodes in breast cancer: the role of intensity-modulated radiotherapy.
    Int J Radiat Oncol Biol Phys, 68(4): 1238-50. [Abstract] [Full-text]
51. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
    Int J Radiat Oncol Biol Phys, 68(4): 1004-9. [Abstract] [Full-text]
52. Selective mastectomy in the management of locally advanced breast cancer.
    Int J Radiat Oncol Biol Phys, 68(4): 1010-7. [Abstract] [Full-text]
53. Can a subgroup of node-negative breast carcinoma patients with T1-2 tumor who may benefit from postmastectomy radiotherapy be identified?
    Int J Radiat Oncol Biol Phys, 68(4): 1024-9. [Abstract] [Full-text]
54. Three-dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy.
    Int J Radiat Oncol Biol Phys, 68(4): 1018-23. [Abstract] [Full-text]
55. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Cancer Res, 67(14): 6825-43. [Abstract] [Full-text]
56. BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines.
    Cancer Res, 67(14): 6725-36. [Abstract] [Full-text]
57. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy.
    Cancer Res, 67(14): 6708-16. [Abstract] [Full-text]
58. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas.
    Cancer Res, 67(14): 6574-81. [Abstract] [Full-text]
59. Development of vaccines for high-risk ductal carcinoma in situ of the breast.
    Cancer Res, 67(14): 6531-4. [Abstract] [Full-text]
60. Pathologic evaluation of cryoprobe-assisted lumpectomy for breast cancer.
    Am J Clin Pathol, 128(2): 239-44. [Abstract] [Full-text]
61. Sexual well-being among partnered women with breast cancer recurrence.
    J Clin Oncol, 25(21): 3151-7. [Abstract] [Full-text]
62. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer.
    J Clin Oncol, 25(21): 3031-7. [Abstract] [Full-text]
63. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.
    J Clin Oncol, 25(21): 3015-23. [Abstract] [Full-text]
64. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
    J Clin Oncol, 25(21): 3007-14. [Abstract] [Full-text]
65. Mammography surveillance and mortality in older breast cancer survivors.
    J Clin Oncol, 25(21): 3001-6. [Abstract] [Full-text]
66. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
    Cell Prolif, 40(4): 488-507. [Abstract] [Full-text]
67. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells.
    Endocrinology, 148(8): 4091-101. [Abstract] [Full-text]
68. DBC2 resistance is achieved by enhancing 26S proteasome-mediated protein degradation.
    Biochem Biophys Res Commun, 360(3): 600-3. [Abstract] [Full-text]
69. Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families.
    BMC Med Genet, 8: 40. [Abstract] [Full-text]
70. High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk.
    BMC Genet, 8: 41. [Abstract] [Full-text]
71. Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer.
    J Clin Oncol, 25(21): 3038-44. [Abstract] [Full-text]
72. Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer.
    J Clin Oncol, 25(21): 3024-30. [Abstract] [Full-text]
73. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study.
    Radiology, 244(2): 381-8. [Abstract] [Full-text]
74. Chromogenic and fluorescent in situ hybridization in breast cancer.
    Hum Pathol, 38(8): 1105-22. [Abstract] [Full-text]
75. Breast mass lesions: computer-aided diagnosis models with mammographic and sonographic descriptors.
    Radiology, 244(2): 390-8. [Abstract] [Full-text]
76. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy.
    Nat Clin Pract Endocrinol Metab, 3(8): 584-93. [Abstract] [Full-text]
77. The prolonged postoperative analgesic effect when dexamethasone is added to a nonsteroidal antiinflammatory drug (rofecoxib) before breast surgery.
    Anesth Analg, 105(2): 481-6. [Abstract] [Full-text]
78. Underestimation of DCIS at MRI-guided vacuum-assisted breast biopsy.
    AJR Am J Roentgenol, 189(2): 468-74. [Abstract] [Full-text]
79. Consumption of soy foods and the risk of breast cancer: findings from the Japan Collaborative Cohort (JACC) Study.
    Cancer Causes Control, 18(8): 801-8. [Abstract] [Full-text]
80. Declines in breast cancer after the WHI: apparent impact of hormone therapy.
    Cancer Causes Control, 18(8): 847-52. [Abstract] [Full-text]
81. Satisfaction with care among patients with non-metastatic breast cancer: development and first steps of validation of the REPERES-60 questionnaire.
    BMC Cancer, 7: 129. [Abstract] [Full-text]
82. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site.
    Cancer Lett, 254(1): 128-36. [Abstract] [Full-text]
83. Vascular occlusions in a patient with low positive antiphospholipid antibodies and subsequent development of breast carcinoma: a diagnostic dilemma.
    Clin Rheumatol, 26(9): 1531-3. [Abstract] [Full-text]
84. In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression.
    Cancer Immunol Immunother, 56(10): 1539-49. [Abstract] [Full-text]
85. Cellular image analysis and imaging by flow cytometry.
    Clin Lab Med, 27(3): 653-70, viii. [Abstract] [Full-text]
86. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
    Int J Pharm, 341(1): 221-9. [Abstract] [Full-text]
87. Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer.
    Int J Cancer, 121(7): 1433-44. [Abstract] [Full-text]
88. Increased expression of the inflammatory protein YKL-40 in precancers of the breast.
    Int J Cancer, 121(7): 1536-42. [Abstract] [Full-text]
89. Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer.
    Int J Cancer, 121(7): 1512-9. [Abstract] [Full-text]
90. Age-period-cohort projections of breast cancer incidence in a rapidly transitioning Chinese population.
    Int J Cancer, 121(7): 1556-63. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.